Company News
Main Concerns from Indian Pharmaceutical Companies about CSC
With many meetings with Indian pharmaceutical companies, we found there are two main concerns about CSC as below:
1. Whether CSC can take very good care of each product since it has signed many products in its basket, especially the management level are wondering if CSC can handle their own products as priority? 
2. CSC now is working with many pharmaceutical companies in India, whether CSC or its partners will always follow the laws and regulations to do the legal business to protect the good market?
For first concern:
1. We have to clarify that the more products we singed and registered the more customers we can cover and it will be much easier to promote new product to our customers as well. So with too many products is actually a big advantage for CSC.
2. Although CSC has signed many products, as for therapeutic use for speaking there are only 9 kinds of products we signed, please kindly refer to below table:



Therapeutic use

Product name



Chlorphenamine Maleate, Fexofenadin Hcl, Loratadine, Cyproheptadine Hcl, Cetirizine DiHcl, Levocetirizine DiHcl, Oxymetazoline Hcl






Metoprolol Tartarate, Amlodipine Besylate, Verapamil Hcl, Lercanidipine Hcl, Perindopril, Atenolol, Reserpine



Pioglitazone Hcl


Digestive system

Rabeprazole Sodium, Domperidone, Lansoprazole, Cisapride


Cerebrovascular disease



Blood system

Ticlopidine Hcl, Clopidogrel Bisulfate






Naltrexone Hcl, Naloxone Hcl

According to above table as a matter of fact we only have 9 kinds of product and to our customers we usually recommend the product package to them, in one hand it will release the workload for the customers so they don’t need to source each product separately, in the other hand we can take good care of every product at the same time which we can treat different products equally. CSC will only expand the products within the certain therapeutic use and provide as much as possible a full range products for our customers’ needs.
3. In order to treat all the products well and equally and to serve all our partners and customers well, CSC now is expanding its sales team which now has around 20 persons and still is recruiting more staff. Meanwhile from 2017 CSC is going to set up regional offices in order to have sustainable communication and provide immediate support to our customers. The sales team is directly led by Mr. Amos who is the AGM of CSC and is very experienced in marketing.
4. CSC also set up a four persons purchase team which is led by Mr. Sam who used to work as business development and had a very good relationship with many Indian partners. Mr. Sam is very familiar with Indian pharmaceutical industry and markets, it is believed that under the leadership of Mr. Sam our purchase team can have a very smooth communication and very good service to our partners.
5. CSC also is expanding the registration team which now is expanded to 10 persons and still is planned to be doubled. Our registration team has established over 12 years since 2005 and successfully got 23 IDLs without any failure case. Meanwhile we have another two persons team especially for DMF and Dossier collection. Also CSC is setting up a branch in Mumbai and recruiting an Indian staff who will be responsible for the coordination and cooperation with our partners and who will provide support and assistance to our partners.
For the second concern: 
We have to clarify that first of all CSC only do legal business in China market and always strictly follow the Chinese laws and CFDA’s regulations, we will not risk our established reputation. Second for all our partners, they are the most beneficiaries who follow the legal way and they are having a very good profit there is no reason for them to break the good rules and risk for the good business. Most of them know to follow the right rules, it will give them the chance to compete and survive in the market.
For all the above examples and actions, CSC will provide better service to our partners and customers.


Copyright © 2013 China Chinopharma Ltd. All rights reserved.